Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
Journal of Clinical Oncology · 2025-11 · 43 (31) · 3381-3390
DOI: 10.1200/jco-25-01694 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025-11. Verfasst von Eunice S Wang und 37 weiteren Autor:innen. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Mutation, Nuclear Proteins. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-001 phase I trial. METHODS In the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1 -m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh). RESULTS From January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events. CONCLUSION Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1 -m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Roswell Park Comprehensive Cancer Center, Buffalo, NY.
- Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL.
- Duke Cancer Institute, Durham, NC.
- Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain.
- Vanderbilt-Ingram Cancer Center, Nashville, TN.
ORCID-Profile: Eunice S Wang, Pau Montesinos, James Foran, Harry Erba, Maël Heiblig, Florian H Heidel, Jessica K Altman, Pierre Peterlin, Céline Berthon, Roland B Walter, Mithun V Shah, Suresh Balasubramanian, Mohamad Khawandanah, Julie Bergeron, Gail J Roboz, Matthew Ulrickson, Arnaud Pigneux, Adolfo de la Fuente Burguera, Ghayas C Issa, Amir T Fathi
Zitieren
APA
Wang, E. S., Montesinos, P., Foran, J., Erba, H., Rodríguez-Arbolí, E., Fedorov, K., Heiblig, M., Heidel, F. H., Altman, J. K., Baer, M. R., Ades, L., Pettit, K., Peterlin, P., Papayannidis, C., Berthon, C., Walter, R. B., Shah, M. V., Balasubramanian, S., Khawandanah, M., …, & KOMET-001 (2025). Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML. Journal of Clinical Oncology, 43(31), 3381-3390. https://doi.org/10.1200/jco-25-01694
Vancouver
Wang ES, Montesinos P, Foran J, Erba H, Rodríguez-Arbolí E, Fedorov K, et al. Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML. Journal of Clinical Oncology. 2025;43(31):3381-3390. doi:10.1200/jco-25-01694
BibTeX
@article{Wang2025,
author = {Wang, Eunice S and Montesinos, Pau and Foran, James and Erba, Harry and Rodríguez-Arbolí, Eduardo and Fedorov, Kateryna and Heiblig, Maël and Heidel, Florian H and Altman, Jessica K and Baer, Maria R and Ades, Lionel and Pettit, Kristen and Peterlin, Pierre and Papayannidis, Cristina and Berthon, Céline and Walter, Roland B and Shah, Mithun V and Balasubramanian, Suresh and Khawandanah, Mohamad and Salamero Garcia, Olga and Bergeron, Julie and Madanat, Yazan F and Roboz, Gail J and Ulrickson, Matthew and Redner, Robert L and McCloskey, James and Pigneux, Arnaud and de la Fuente Burguera, Adolfo and Mitra, Amitava and Soifer, Harris S and Tabachri, Marilyn and Zhang, Zijing and Riches, Marcie and Corum, Daniel and Leoni, Mollie and Issa, Ghayas C and Fathi, Amir T and KOMET-001, KOMET-001},
title = {Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {31},
pages = {3381--3390},
doi = {10.1200/jco-25-01694}
}
EUVIMED